
Shares of Novavax Inc (NASDAQ:NVAX) are trading lower Friday morning, appearing to be caught in a downdraft affecting COVID-19 vaccine makers after rival Moderna Inc (NASDAQ:MRNA) reported disappointing second-quarter financial results and cut its full-year forecast.
What To Know: Moderna announced on Friday a significant second-quarter loss of $2.12 per share, substantially missing analyst expectations of a 93 cent per share loss.